Novel potent and selective antagonist of exportin-1, attenuating dual NF-κB signaling and the Nrf2 cytoprotection pathway via targeting exportin-1 in colitis mice

Hematologic malignancy-selective membranolytic peptide from the antimicrobial core (RRWQWR) of bovine lactoferricin

Selective estrogen receptor modulator (SERM)

Neuroprotective, anti-inflammatory, and anti-diabetic agent, protecting against DNA damage and apoptosis induced by ultraviolet light

Respiratory quinolone antibiotic, exhibiting enhanced activity against the important respiratory pathogen Streptococcus pneumoniae

Natural carnitine derivative, playing a role in mitochondrial metabolism and demonstrating beneficial cardiovascular effects

Watersoluble prodrug of Levcromakalim, being more chemically robust and efficacious at lowering IOP with once daily dosing in a normotensive mouse model.

Partial agonist (antagonist) at mu and delta opioid receptors.

Inhibitor of ERAAP function

Leukotriene B4 receptor antagonist

Orally bioavailable Smoothened (Smo) antagonist

Novel Soft-Drug Inhibitor of Phosphodiesterase 4 (PDE4) for Topical Treatment of Atopic Dermatitis

Novel non-steroidal glucocorticoid receptor agonist

Phosphodiesterase inhibitor, acting as a vasodilator and showing antihypertensive effects

Novel Electrophilic PROTAC that degrades nuclear proteins by engaging DCAF16

Novel inhibitor of T-cell expansion and autoimmune encephalomyelitis

Novel inhibitor of nuclear receptor binding SET domain 2 (NSD2), against H3K36 methylation

Novel potent inhibitor for the PLAAT family members, reducing the NAE levels, including anandamide, in cells overexpressing PLAAT2 or PLAAT5

Novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist

Cyclooxygenase-2 (COX-2) inhibitor

Novel inhibitor of the LEDGF/p75-IN interaction, potently inhibiting both the early and late stages of HIV-1 replication

Highly potent multi-target antagonists of alpha1A- and alpha1D-adrenoceptors, and 5-HT1A receptors

Highly potent multi-target antagonists of both alpha1A- and alpha1D-adrenoceptors, and also of 5-HT1A receptors

Novel partial agonist of PPARα and PPARγ, providing distinct and favorable gene activation profiles for the treatment of diabetes and obesity

Highly potent multi-target antagonists of both alpha1A- and alpha1D-adrenoceptors, and also of 5-HT1A receptors

Nucleic acid binding fluorescent dye

Precursor of 6-[18F]Fluoro-L-DOPA used for positron emission tomography (PET) scans. References: http://www.hindawi.com/journals/bmri/2014/674063/

Competitive LRRK2 kinase inhibitor without affecting the GTPase activity

Novel ALK2 inhibitor

Potent haspin kinase inhibitor